<DOC>
	<DOCNO>NCT00713310</DOCNO>
	<brief_summary>The overall objective study assess safety efficacy high dose low dose Asacol administer 400 mg delayed-release tablet give every 12 hour 6 week child adolescent mildly-to-moderately active ulcerative colitis .</brief_summary>
	<brief_title>Assessing Safety/Efficacy AsacolÂ® Given Every 12 Hours Children Adolescents With Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>male female age 5 17 year , inclusive , time first dose study medication , history biopsy endoscopy confirm UC ; mildlytomoderately active UC ( either newly diagnose relapse ) define clinically Pediatric UC Activity Index ( PUCAI ) score 10 55 , , opinion Investigator , patient require steroid ; baseline score least 1 rectal bleeding ( Streaks blood stool less half time ) stool frequency ( 12 stools great normal per day ) define TMMayo Score UC know confine rectum ( isolated rectal proctitis ) ; history allergy hypersensitivity salicylate , aminosalicylates , component Asacol tablet ; significant coexisting illness condition ( ) , include limited cancer significant organic psychiatric disease medical history physical examination , , judgment Investigator , contraindicate ( ) administration study drug and/or study procedure</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>